Furthermore, in vivo CRISPR screens under various immune contexts revealed that Sephs1-deficient tumor cells were negatively selected, implying decreased fitness under immune pressure (Fig. 2D, Table S6). This evidence concerns the gene SEPHS1 and neoplasm.